已发表论文

FAK家族激酶:动脉粥样硬化的潜在治疗靶点

 

Authors Guan X, Liu Y, An Y, Wang X, Wei L, Qi X 

Received 24 February 2024

Accepted for publication 13 August 2024

Published 26 August 2024 Volume 2024:17 Pages 3151—3161

DOI https://doi.org/10.2147/DMSO.S465755

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Muthuswamy Balasubramanyam

Xiuju Guan,1 Yue Liu,2 Yajuan An,1 Xinshuang Wang,1 Liping Wei,2 Xin Qi2 

1School of Graduate Studies, Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Department of Cardiology, Tianjin Union Medical Center, Tianjin, People’s Republic of China

Correspondence: Xin Qi, Email qixinx2011@126.com

Abstract: Atherosclerosis (AS) is a chronic progressive inflammatory disease of the vascular wall and the primary pathological basis of cardiovascular and cerebrovascular disease. Focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), two highly homologous members of the FAK family kinases, play critical roles in integrin signaling. They also serve as scaffolding proteins that contribute to the assembly of cellular signaling complexes that regulate cell survival, cell cycle progression, and cell motility. Research indicates that the FAK family kinases is involved in the gene regulation of vascular cells and that aberrant expression of this family is associated with pathological changes in vascular disease. These findings establish the FAK family kinases as a critical signaling mediator in atherosclerotic lesions and inhibition of its activity has the potential to attenuate the pathological progression of AS. This review highlights the indispensable role of the FAK family kinases in abnormal vascular smooth muscle cell proliferation, endothelial cell dysfunction, inflammation, and lipid metabolism associated with AS. We also summarize therapeutic targets against the FAK family kinases, providing valuable insights into therapeutic strategies for AS.

Keywords: FAK family kinases, atherosclerosis, inhibitors, cellular signaling